
|Articles|May 26, 2013
Supplements and Featured Publications
- Addressing the Clinical and Managed Care Challenges in Treating Diseases of the Aging Eye [CPE]
- Volume 19
- Issue 5 Suppl
Addressing the Clinical and Managed Care Challenges in Treating Diseases of the Aging Eye
Advertisement
Instructions
After reading “Addressing the Clinical and Managed Care Challenges in Treating Diseases of the Aging Eye,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
over 13 years ago
Managed Care Implications of Age-Related Ocular Conditionsover 13 years ago
Current Treatment Strategies for Age-Related Ocular Conditionsover 13 years ago
Overview of Age-Related Ocular ConditionsAdvertisement
Related to this article

After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.

Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.

The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.

Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
Health Equity & Access Weekly Roundup: November 6, 2026
4
GLP-1 RAs Improve MASLD, MASH Markers, but Long-Term Benefits Unclear
5

